dimethyl 1,4-dihydro-2,6-dimethyl-4-(1-naphthyl)-3,5-dicarboxylate | 50672-60-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: dimethyl 1,4-dihydro-2,6-dimethyl-4-(1-naphthyl)-3,5-dicarboxylate
• 英文别名: dimethyl 2,6-dimethyl-4-(1-naphthyl)-1,4-dihydropyridine-3,5-dicarboxylate；Dimethyl 2,6-dimethyl-4-(naphthalen-1-yl)-1,4-dihydropyridine-3,5-dicarboxylate；dimethyl 2,6-dimethyl-4-naphthalen-1-yl-1,4-dihydropyridine-3,5-dicarboxylate
• CAS: 50672-60-1
• 化学式: C₂₁H₂₁NO₄
• 分子量: 351.402
• InChiKey: JJRQTRMWIZKCMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  dimethyl 1,4-dihydro-2,6-dimethyl-4-(1-naphthyl)-3,5-dicarboxylate 在 potassium phosphate 、 乙二胺四乙酸 、 Emulgen 911 、 human liver cytochrome b₅ 、 human liver HL 39 lipid extract 、 rabbit liver NADPH-P-450 reductase 、 yeast P-450 IIIA₄ 、 magnesium chloride 作用下， 以 水 为溶剂， 生成 2,6-Dimethyl-4-naphthalen-1-yl-pyridine-3,5-dicarboxylic acid dimethyl ester
  参考文献：
  名称：

  Oxidation of dihydropyridine calcium channel blockers and analogs by human liver cytochrome P-450 IIIA4

  摘要：

  A series of 21 different 4-substituted 2,6-dimethyl-3-(alkoxycarbonyl)-1,4-dihydropyridines was considered with regard to oxidation to pyridine derivatives by human liver microsomal cytochrome P-450 (P-450). Antibodies raised against P-450 IIIA4 inhibited the microsomal oxidation of nifedipine and felodipine to the same extent, as did cimetidine and the mechanism-based inactivator gestodene. Gestodene was approximately 10(3) times more effective an inhibitor than cimetidine, on a molar basis. When rates of oxidation of the 1,4-dihydropyridines were compared to each other in different human liver microsomal preparations, all were highly correlated with each other with the exceptions of a derivative devoid of a substituent at the 4-position and an N1-CH3 derivative. A P-4.50 IIIA4 cDNA clone was expressed in yeast and the partially purified protein was used in reconstituted systems containing NADPH-cytochrome P-450 reductase and cytochrome b5. This system catalyzed the oxidation of all of the 1,4-dihydropyridines except the two for which poor correlation was seen in the liver microsomes. Principal component analysis supported the view that most of these reactions were catalyzed by the same enzyme in the yeast P-450 IIIA4 preparation and in the different human liver microsomal preparations, or by a closely related enzyme showing nearly identical properties of catalytic specificity and regulation. The results indicate that the enzyme P-450 IIIA4 is probably the major human catalyst involved in the formal dehydrogenation of most but not all 1,4-dihydropyridine drugs.

  DOI：

  10.1021/jm00110a012
• 作为产物：
  描述：

  1-萘甲醛 、 乙酰乙酸甲酯 在 ammonium hydroxide 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 dimethyl 1,4-dihydro-2,6-dimethyl-4-(1-naphthyl)-3,5-dicarboxylate
  参考文献：
  名称：

  N-Alkylated 1,4-Dihydropyridines: New Agents to Overcome Multidrug Resistance.

  摘要：

  新合成的N-烷基化1,4-二氢吡啶衍生物，在长春新碱耐药的P388细胞（P388/VCR细胞）中检测了其克服多药耐药的能力。在二氢吡啶环氮上带有芳烷基取代基的化合物，比维拉帕米更能增强长春新碱对P388/VCR细胞的细胞毒性。然而，这两种药物均未有效地增强长春新碱在携带肿瘤的小鼠中的抗肿瘤活性。在1,4-二氢吡啶的侧链上引入含有碱性氮的取代基，在体外和体内均能提高活性。哌嗪衍生物12c和12o在体外比维拉帕米强10倍以上。选出四种化合物进行体内测试，它们与长春新碱联合使用时，在携带P388/VCR的肿瘤小鼠中显示出优越的抗肿瘤活性。讨论了化合物的构效关系。

  DOI：

  10.1248/cpb.43.818

文献信息

• N-Alkylated 1,4-Dihydropyridines: New Agents to Overcome Multidrug Resistance.
  作者：Koji OHSUMI、Kazuo OHISHI、Yoshihiro MORINAGA、Ryusuke NAKAGAWA、Yasuyo SUGA、Takaaki SEKIYAMA、Yukio AKIYAMA、Takashi TSUJI、Takashi TSURUO

  DOI：10.1248/cpb.43.818

  日期：——

  New N-alkylated 1, 4-dihydropyridine derivatives were synthesized and their ability to overcome multidrug resistance was examined in vincristine-resistant P388 cells (P388/VCR cells). Compounds that possessed an arylalkyl substituent on the dihydropyridine ring nitrogen were more potent than verapamil in potentiating the cytotoxicity of vincristine against P388/VCR cells. However, neither drug effectively enhanced the antitumor activity of vincristine in tumor-bearing mice. Introduction of basic nitrogen-containing substituents on the side chain of 1, 4-dihydropyridines gave improved activity in vitro and in vivo. The piperazine derivative 12c and 12o were more than 10 times as potent as verapamil in vitro. Four compounds selected for in vivo testing showed superior antitumor activity in P388/VCR-bearing mice in combination with vincristine. The structure-activity relationships of the compounds are discussed.

  新合成的N-烷基化1,4-二氢吡啶衍生物，在长春新碱耐药的P388细胞（P388/VCR细胞）中检测了其克服多药耐药的能力。在二氢吡啶环氮上带有芳烷基取代基的化合物，比维拉帕米更能增强长春新碱对P388/VCR细胞的细胞毒性。然而，这两种药物均未有效地增强长春新碱在携带肿瘤的小鼠中的抗肿瘤活性。在1,4-二氢吡啶的侧链上引入含有碱性氮的取代基，在体外和体内均能提高活性。哌嗪衍生物12c和12o在体外比维拉帕米强10倍以上。选出四种化合物进行体内测试，它们与长春新碱联合使用时，在携带P388/VCR的肿瘤小鼠中显示出优越的抗肿瘤活性。讨论了化合物的构效关系。
• [EN] MINERALOCORTICOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS MINÉRALOCORTICOÏDES
  申请人：MERCK & CO INC

  公开号：WO2009078934A1

  公开（公告）日：2009-06-25

  The present invention relates to dihydropyridine mineralcorticoid receptor modulating compounds having the structure: and their use in treating cardiovascular events.

  本发明涉及具有以下结构的二氢吡啶矿物皮质激素受体调节化合物：以及它们在治疗心血管事件中的用途。
• Chiral Phosphoric Acid Catalyzed Enantioselective Desymmetrization of 1,4‐Dihydropyridines by C(sp ³ )−H Bromination
  作者：Min Han、Shi‐qi Zhang、Xin Cui、Qi‐wei Wang、Guang‐xun Li、Zhuo Tang

  DOI：10.1002/anie.202201418

  日期：2022.5.23

  used as substrates to obtain chiral Hantzsch-type 1,4-DHPs, which are frequently contained in pharmaceuticals. The inert C−H bond was converted into a versatile C−Br bond, which enabled the modification of the chiral 1,4-DHP derivatives with high efficiency by nucleophilic substitution. Furthermore, axially chiral 4-aryl pyridines were accessible by central-to-axial chirality conversion.

  容易获得的对称 1,4-二氢吡啶 (1,4-DHP) 被用作底物以获得药物中经常含有的手性 Hantzsch 型 1,4-DHP。惰性 C-H 键被转化为通用的 C-Br 键，从而能够通过亲核取代高效地修饰手性 1,4-DHP 衍生物。此外，轴向手性 4-芳基吡啶可通过中心到轴向手性转换获得。
• MINERALOCORTICOID RECEPTOR MODULATORS
  申请人：Brandish Philip E.

  公开号：US20100261765A1

  公开（公告）日：2010-10-14

  The present invention relates to dihydropyridine mineralocorticoid receptor modulating compounds having the structure: and their use in treating cardiovascular events.

  本发明涉及具有以下结构的二氢吡啶矿物质皮质激素受体调节化合物及其在治疗心血管事件中的应用。
• Oxidation of dihydropyridine calcium channel blockers and analogs by human liver cytochrome P-450 IIIA4
  作者：F. Peter Guengerich、William R. Brian、Masahiko Iwasaki、Marie Agnes Sari、Catharina Baeaernhielm、Peder Berntsson

  DOI：10.1021/jm00110a012

  日期：1991.6

  A series of 21 different 4-substituted 2,6-dimethyl-3-(alkoxycarbonyl)-1,4-dihydropyridines was considered with regard to oxidation to pyridine derivatives by human liver microsomal cytochrome P-450 (P-450). Antibodies raised against P-450 IIIA4 inhibited the microsomal oxidation of nifedipine and felodipine to the same extent, as did cimetidine and the mechanism-based inactivator gestodene. Gestodene was approximately 10(3) times more effective an inhibitor than cimetidine, on a molar basis. When rates of oxidation of the 1,4-dihydropyridines were compared to each other in different human liver microsomal preparations, all were highly correlated with each other with the exceptions of a derivative devoid of a substituent at the 4-position and an N1-CH3 derivative. A P-4.50 IIIA4 cDNA clone was expressed in yeast and the partially purified protein was used in reconstituted systems containing NADPH-cytochrome P-450 reductase and cytochrome b5. This system catalyzed the oxidation of all of the 1,4-dihydropyridines except the two for which poor correlation was seen in the liver microsomes. Principal component analysis supported the view that most of these reactions were catalyzed by the same enzyme in the yeast P-450 IIIA4 preparation and in the different human liver microsomal preparations, or by a closely related enzyme showing nearly identical properties of catalytic specificity and regulation. The results indicate that the enzyme P-450 IIIA4 is probably the major human catalyst involved in the formal dehydrogenation of most but not all 1,4-dihydropyridine drugs.